Original Article
Relapses and Progression of Disability in Multiple Sclerosis
N Engl J Med 2000; 343:1430-1438November 16, 2000
- Abstract
Background
The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of irreversible disability is controversial.
Methods
In 1844 patients who had had multiple sclerosis for a mean (±SD) of 11±10 years, we determined the time of the clinical onset of the disease, the initial course (relapsing–remitting or progressive) and the subsequent course (relapsing–remitting, secondary progressive, or primary progressive), the times of relapses, the time to the onset of irreversible disability, and the time course of progressive, irreversible disability. We used three scores on the Kurtzke Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability) as measures of the severity and progression of disability: a score of 4 (limited walking ability but able to walk more than 500 m without aid or rest), a score of 6 (ability to walk with unilateral support no more than 100 m without rest), and a score of 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support). We used Kaplan–Meier analyses to determine the influence of relapses on the time to the onset of irreversible disability.
Results
The median times from the onset of multiple sclerosis to the assignment of a score of 4, a score of 6, and a score of 7 on the disability scale were longer among the 1562 patients with a relapsing–remitting onset of disease (11.4, 23.1, and 33.1 years, respectively) than among the 282 patients who had progressive disease from the onset (0.0, 7.1, and 13.4 years, respectively; P<0.001 for all comparisons). In contrast, the times from the assignment of a score of 4 to a score of 6 were similar in the two groups (5.7 and 5.4 years, P=0.74). The time course of progressive, irreversible disease among patients with the primary progressive type of multiple sclerosis was not affected by the presence or absence of superimposed relapses.
Conclusions
Among patients with multiple sclerosis, relapses do not significantly influence the progression of irreversible disability. (N Engl J Med 2000; 343:1430-8.)
Media in This Article
Figure 2
Kaplan–Meier Estimates of the Time from the Onset of Multiple Sclerosis to the Assignment of a Score of 4 on the Kurtzke Disability Status Scale (Panel A), the Time from the Assignment of a Score of 4 to a Score of 6 (Panel B), and the Time from the Assignment of a Score of 6 to a Score of 7 (Panel C) among 1844 Patients with Multiple Sclerosis, According to the Initial Course.Figure 1
Overall Course and Type of Multiple Sclerosis in the Study Patients.Article Activity
- Article
Multiple sclerosis is the most common chronic disabling disease of the central nervous system in young adults. It affects 1 in 1000 people in Western countries.1 It is primarily characterized by multicentric inflammation and demyelination, but the role of axonal injury and gliosis increases as the disease evolves.2 In most patients the disease begins at about 30 years of age with acute episodes of neurologic dysfunction, followed by periods of partial or complete remission with clinical stability between relapses — the relapsing–remitting phase of the disease. Except in patients with the relapsing–remitting type of multiple sclerosis, this phase is usually followed by progressive clinical disability, with or without superimposed relapses and remissions.3-5 In a minority of patients, the disease is progressive from the beginning, although there may be superimposed relapses and remissions. Therefore, neurologic disability may result from relapses with incomplete remissions, progression of the disease, or both.
Since 1993, two drugs — interferon beta and glatiramer acetate — have been identified as disease-modifying treatments.6-10 These drugs reduce the frequency of relapses by about one third but are less effective in slowing the progression of disability.8-10 The objective of this study was to determine the influence of acute relapses on the rate of progression of irreversible disability in patients with multiple sclerosis.
Methods
Patient Population and Data Collection
Patients were identified through the Lyons multiple sclerosis data base.3 This computerized surveillance system was established in 1976 and includes all patients with a diagnosis of multiple sclerosis who were examined at least once at the Clinique de Neurologie in Lyons, France. This clinic has served as the referral center for multiple sclerosis for the city of Lyons and the Rhône–Alpes region since 1976. Decisions regarding diagnostic tests and treatments for individual patients were made by referring neurologists or neurologists in the clinic, or both, according to accepted guidelines. Relapses were usually treated with glucocorticoids. Since the late 1960s, azathioprine and cyclophosphamide have been used to treat multiple sclerosis. Azathioprine is administered mainly during the relapsing–remitting phase of multiple sclerosis and after the third relapse, and it is usually stopped when the disease becomes progressive. Cyclophosphamide therapy is used only in severe cases or during the progressive phase of the disease. A single, intense course may be given, or long-term treatment may be given, but it usually lasts no longer than 12 months. Since the early 1990s, methotrexate has been used, usually for no more than 12 months, in some patients with the secondary progressive type of multiple sclerosis.
Each case report in the data base includes identifying and demographic data, medical history, key episodes in the course of the disease (relapses, onset of progressive disease, and onset of irreversible, progressive disability), results of laboratory and electrophysiologic tests, neuroimaging data, and treatment. Data are entered retrospectively when the patient is first seen at the clinic and at each follow-up visit, usually on a yearly basis. Since 1990, data have been recorded on the standardized computerized forms designed for the European Database for Multiple Sclerosis.11 New data are automatically compared with older information, and any inconsistencies are identified. The confidentiality of the data is maintained in accordance with the recommendations of the French Commission Nationale de l'Informatique et des Libertés. All patients gave informed consent to have their data included in the data base.
Definition of Cases
By April 1997, 2021 patients had been included in the data base. Multiple sclerosis was diagnosed according to the classification of Poser et al.12 This classification scheme relies on three criteria: dissemination of lesions in time (there must be at least two distinct neurologic episodes in the course of the disease); evidence of spatial dissemination of lesions in the central nervous system, provided by clinical findings or magnetic resonance imaging, computed tomography, or testing of evoked potentials; and quantitative or qualitative abnormalities of immunoglobulins in the cerebrospinal fluid. Cases are considered clinically definite when the first two criteria are met, regardless of the results of cerebrospinal fluid tests; laboratory-supported definite cases meet the first and third criteria or the second and third criteria; clinically probable cases meet the first criterion or the second criterion; laboratory-supported probable cases meet the third criterion; and possible cases do not fulfill any of the criteria but are characterized by neurologic abnormalities that are compatible with the diagnosis of multiple sclerosis.
Assessment of Patients
A relapse of multiple sclerosis was defined as the occurrence, the recurrence, or the worsening of symptoms of neurologic dysfunction that lasted more than 24 hours and that stabilized or eventually resolved either partially or completely. Fatigue alone and transient fever-related worsening of symptoms were not considered relapses. Symptoms that occurred within a month after the initial symptoms of relapse were considered to be part of the same episode.
The onset of progressive disease was defined as a continual worsening of symptoms and signs for a period of at least six months, with or without superimposed relapses.13 Once progression has developed, its course is continuous, although occasional plateaus and temporary minor improvements may occur.5
Neurologic disability was assessed at each visit to the clinic with use of the Kurtzke Disability Status Scale,14 which is based on the results of a neurologic examination and the patient's ability to walk. Scores can range from 0 (no neurologic abnormality) to 10 (death from multiple sclerosis). We focused on scores that could be easily determined retrospectively: scores of 4 (limited walking ability but able to walk without aid or rest for more than 500 m), 6 (ability to walk with unilateral support no more than 100 m without rest), and 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support). Disability was defined as irreversible when a patient had had a given score for at least six months, excluding any transient worsening of disability related to relapses.
Statistical Analysis
Survival was estimated according to the Kaplan–Meier method, and the log-rank test was used for univariate analyses. The end point was the time to irreversible disability, as indicated by a score of 4, 6, or 7 on the Kurtzke Disability Status Scale. All computations were performed with the use of SPSS software for Windows (version 9.0).15
Results
Characteristics of the Patients
Of the 2021 patients who were potentially eligible for the study, 170 were excluded because they had possible cases according to the classification of Poser et al.12 and 7 were excluded because their initial symptoms were unknown (Figure 1Figure 1
Overall Course and Type of Multiple Sclerosis in the Study Patients.). The base-line characteristics of the remaining 1844 patients with a definite or probable diagnosis of multiple sclerosis are given in Table 1Table 1
Base-Line Characteristics of the 1844 Patients with Multiple Sclerosis..A total of 903 patients (49 percent) had received one or more drugs for multiple sclerosis. The most widely used treatment was azathioprine (given to 820 patients), followed by cyclophosphamide (given to 78), interferon beta (given to 72), methotrexate (given to 60), and mitoxantrone (given to 18). As compared with the patients who had not received such drugs, the treated patients had a higher frequency of relapses and a more severe initial course of the disease, findings that presumably reflect a selection bias with respect to the use of drug therapy. Treatment status did not affect the results of our analyses. However, it should be noted that the only treatment with proven efficacy is interferon beta, and the first of these interferons, interferon beta-1b, was not available in our area until February 1996. Moreover, the treatment regimens were heterogeneous, and treatments were usually given for fairly short periods relative to the overall duration of the disease in a given patient.
Initial Course of Multiple Sclerosis and Time to Onset of Irreversible Disability
A total of 1562 patients (85 percent) had relapsing–remitting disease initially, whereas 282 patients (15 percent) had progressive disease. In the entire group of 1844 patients, the median time from the onset of multiple sclerosis to the assignment of a score of 4 on the Kurtzke Disability Status Scale was 8.4 years (95 percent confidence interval, 7.8 to 9.6). The median time from onset of multiple sclerosis to the assignment of a score of 6 was 20.1 years (95 percent confidence interval, 18.1 to 22.5), and the median time from the onset of disease to the assignment of a score of 7 was 29.9 years (95 percent confidence interval, 25.1 to 34.5). The median interval from the onset of disease to the assignment of each of these scores was significantly longer (P<0.001 for each comparison) in the group of patients with a relapsing–remitting onset of disease than among those who had progressive disease at onset (Table 2Table 2
Kaplan–Meier Estimates of the Median Time from the Onset of Multiple Sclerosis to the Onset of Irreversible Disability among 1844 Patients with Multiple Sclerosis, According to the Initial Course. and Figure 2Figure 2Kaplan–Meier Estimates of the Time from the Onset of Multiple Sclerosis to the Assignment of a Score of 4 on the Kurtzke Disability Status Scale (Panel A), the Time from the Assignment of a Score of 4 to a Score of 6 (Panel B), and the Time from the Assignment of a Score of 6 to a Score of 7 (Panel C) among 1844 Patients with Multiple Sclerosis, According to the Initial Course.).Initial Course of Multiple Sclerosis and the Time Course of Progressive, Irreversible Disability
Among the 1844 patients, 1026 patients (56 percent) reached the end point of a score of 4 on the Kurtzke Disability Status Scale during follow-up. In this group, the median time from the assignment of a score of 4 to the assignment of a score of 6 was 5.7 years (95 percent confidence interval, 5.0 to 6.3). The median time from the assignment of a score of 4 to the assignment of a score of 7 was 12.1 years (95 percent confidence interval, 10.3 to 13.9). Similarly, 595 patients (32 percent) reached the end point of a score of 6. In this group, the median time from the assignment of a score of 6 to the assignment of a score of 7 was 3.4 years (95 percent confidence interval, 3.0 to 3.8). The median times required for each of these changes to occur were similar whether the disease was initially relapsing–remitting or progressive (Table 2 and Figure 2).
Effect of Superimposed Relapses during the Progressive Phase on the Time Course of Progressive, Irreversible Disability
Among patients with the secondary progressive type of multiple sclerosis, the median time from the assignment of a score of 4 on the Kurtzke Disability Status Scale to the assignment of a score of 6 was not influenced by the presence or the absence of superimposed relapses (Table 3Table 3
Kaplan–Meier Estimates of the Median Time Course of Progressive, Irreversible Disability among Patients with the Primary or Secondary Type of Progressive Multiple Sclerosis, According to the Presence or Absence of Superimposed Relapses. and Figure 3Figure 3
Kaplan–Meier Estimates of the Time from the Assignment of a Score of 4 on the Kurtzke Disability Status Scale to the Assignment of a Score of 6 among the 496 Patients with the Secondary Progressive Type of Multiple Sclerosis (Panel A) and the 282 Patients with the Primary Progressive Type of Multiple Sclerosis (Panel B), According to the Presence or Absence of Superimposed Relapses.). In contrast, the median time from the assignment of a score of 4 to a score of 7 and from a score of 6 to a score of 7 was longer among patients with the secondary progressive type who had superimposed relapses than among patients with this type of multiple sclerosis who did not have superimposed relapses (Table 3). Among patients with the primary progressive type of multiple sclerosis, the median time from the assignment of a score of 4 to a score of 6 or 7 or from a score of 6 to a score of 7 was not influenced by the presence or the absence of superimposed relapses (Table 3 and Figure 3).Discussion
In this observational study of the natural history of multiple sclerosis, we found that irreversible disability occurred sooner in patients in whom the disease was progressive from its onset than in those in whom the onset was relapsing–remitting. In contrast, once irreversible disability occurred, the time course of progressive disability was similar in the two groups. In addition, the time course of progressive, irreversible disability among patients with the primary progressive type of multiple sclerosis was not significantly influenced by the presence or absence of superimposed relapses. Among patients with the secondary type of multiple sclerosis (which occurs after a relapsing–remitting phase), the time course of the progressive phase of the disease was longer among patients who had superimposed relapses than among those who did not have superimposed relapses.
The Lyons multiple sclerosis data base is probably among the largest and oldest of such registries. Data on patients with multiple sclerosis who were referred to and subsequently followed in the clinic are entered in the data base by a group of neurologists who use commonly accepted guidelines and a standardized approach.11 In terms of their demographic characteristics, clinical course, and prognosis, our cohort of patients is similar to those in other major published studies.4,16,17
The first validated disease-modifying drug for multiple sclerosis, interferon-beta 1b,6 became available in France in February 1996. Approximately half of our patients have received immunosuppressive drugs — azathioprine, in most cases — for some period of time; none of these drugs have a commonly recognized specific effect on the course of multiple sclerosis.18
Our results are in accordance with and extend those of other large studies of the natural history of multiple sclerosis. A group of Canadian researchers showed that, as compared with patients with the primary progressive type of multiple sclerosis, patients with the secondary progressive type had a slower onset of disability but a faster progression of the disability.19 The same group also showed that the survival curves were almost identical for patients with the primary progressive type of multiple sclerosis who had superimposed relapses and patients with the primary progressive type who did not have superimposed relapses with respect to the time from the onset of disease to the assignment of a score of 6, a score of 8, and death.20 Others have reached similar conclusions with respect to the time from the onset of primary progressive multiple sclerosis to the assignment of a score of 6.21
Relapses and progression are the two basic clinical phenomena of multiple sclerosis. Relapses are considered to be the clinical expression of acute inflammatory focal lesions disseminated in the central nervous system, whereas progression is considered to reflect the occurrence of demyelination, axonal loss, and gliosis. We found that once a clinical threshold of irreversible disability has been reached (a score of 4 on the Kurtzke Disability Status Scale), the progression of disability is not affected by relapses, either those that occur before the onset of the progressive phase or those that supervene during this phase. The absence of a relation between relapses and irreversible disability suggests that there is a dissociation at the biologic level between recurrent acute focal inflammation and progressive degeneration of the central nervous system. This apparent paradox is consistent with the persistence of the progression of disability in patients with multiple sclerosis despite infection with the human immunodeficiency virus22 or despite suppression of the cerebral inflammation after treatment with a potent antileukocyte monoclonal antibody.23 It also suggests that agents that have a short-term effect on relapses in patients with multiple sclerosis may not necessarily delay the development of disability in the long term.
Supported by contracts with the Commission of the European Communities Directorate General XII (BMH1-CT93-1529, CIPD-CT94-0227, BMH4-CT96-0064) and by funds from the Ligue Française contre la Sclérose en Plaques.
We are indebted to the patients for their participation in the Lyons multiple sclerosis data base; to Mr. Albert Biron for maintaining the data base; to Drs. Marie-Françoise Belin, Patricia Saddier, and Rachid Salmi for helpful discussions about the paper; and to Mrs. Isabelle Pairel for assistance in preparing the manuscript.
Source Information
From the European Database for Multiple Sclerosis Coordinating Center and Service de Neurologie A, Hôpital Neurologique (C.C., S.V., T.M.); and Unité de Biostatistique et Informatique Médicale, Hospices Civils de Lyon (P.A.) — both in Lyons, France.
Address reprint requests to Dr. Confavreux at the EDMUS Coordinating Center and Service de Neurologie A, Hôpital Neurologique, 59 Blvd. Pinel, 69394 Lyons CEDEX 03, France.
- References
References
1
Sadovnick AD ,Ebers GC . Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993;20:17-29
Web of Science | Medline2
Trapp BD ,Peterson J ,Ransohoff RM ,Rudick R ,Mork S ,Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285
Full Text | Web of Science | Medline3
Confavreux C ,Aimard G ,Devic M . Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300
CrossRef | Web of Science | Medline4
Weinshenker BG ,Bass B ,Rice GPA , et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146
CrossRef | Web of Science | Medline5
Lublin FD ,Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911
Web of Science | Medline6
The IFNB Multiple Sclerosis Study Group
Web of Science | Medline7
Johnson KP ,Brooks BR ,Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
Web of Science | Medline8
Jacobs LD ,Cookfair DL ,Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294[Erratum, Ann Neurol 1996;40:480.]
CrossRef | Web of Science | Medline9
PRISMS (Prevention of Relapses and Disability by Interferon (beta)-1a Subcutaneously in Multiple Sclerosis) Study Group
CrossRef | Web of Science | Medline10
European Study Group on Interferon (beta)-1b in Secondary Progressive MS
CrossRef | Web of Science | Medline11
Confavreux C ,Compston DAS ,Hommes OR ,McDonald WI ,Thompson AJ . EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-676
CrossRef | Web of Science | Medline12
Poser CM ,Paty DW ,Scheinberg L , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
CrossRef | Web of Science | Medline13
Schumacher GA ,Beebe G ,Kibler RF , et al. Problems of experimental trials of therapy in multiple sclerosis: report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965;122:552-568
CrossRef | Web of Science | Medline14
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452
Web of Science | Medline15
Statistical package for social science, release 9.0. Chicago: SPSS, 1999 (software).
16
Phadke JG . Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-1628
CrossRef | Web of Science | Medline17
Runmarker B ,Andersen O . Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134
CrossRef | Web of Science | Medline18
Rudick RA ,Cohen JA ,Weinstock-Guttman B ,Kinkel RP ,Ransohoff RM . Management of multiple sclerosis. N Engl J Med 1997;337:1604-1611
Full Text | Web of Science | Medline19
Cottrell DA ,Kremenchutzky M ,Rice GPA , et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-639
CrossRef | Web of Science | Medline20
Kremenchutzky M ,Cottrell D ,Rice G , et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941-1950
CrossRef | Web of Science | Medline21
Andersson PB ,Waubant E ,Gee L ,Goodkin DE . Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 1999;56:1138-1142
CrossRef | Web of Science | Medline22
Berger JR ,Sheremata WA ,Resnick L ,Atherton S ,Fletcher MA ,Norenberg M . Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology 1989;39:324-329
Web of Science | Medline23
Coles AJ ,Wing MG ,Molyneux P , et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
CrossRef | Web of Science | Medline
- Citing Articles (226)
Citing Articles
1
Loredana La Mantia, Laura Vacchi, Carlo Di Pietrantonj, George Ebers, Marco Rovaris, Sten Fredrikson, Graziella Filippini, Loredana La Mantia. 2012. Interferon beta for secondary progressive multiple sclerosis. .
CrossRef2
M. Pallix-Guyot, A.-M. Guennoc, H. Blasco, B. de Toffol, P. Corcia, J. Praline. (2011) Predictive value of motor evoked potentials in clinically isolated syndrome. Acta Neurologica Scandinavica 124:6, 410-416
CrossRef3
J. C. Gibson, G. D. Summers. (2011) Bone health in multiple sclerosis. Osteoporosis International 22:12, 2935-2949
CrossRef4
Giancarlo Comi, Nicola De Stefano, Mark S Freedman, Frederik Barkhof, Chris H Polman, Bernard MJ Uitdehaag, Florence Casset-Semanaz, Brian Hennessy, Margaretha Stam Moraga, Sanda Rocak, Bettina Stubinski, Ludwig Kappos. (2011) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. The Lancet Neurology
CrossRef5
L. H. Visser, A. van der Zande. (2011) Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. European Journal of Neurology 18:11, 1343-1349
CrossRef6
A. Déniz Cáceres, P. Saavedra, I. Marrero. (2011) Predicción del grado de minusvalía en pacientes con esclerosis múltiple. Rehabilitación 45:4, 301-307
CrossRef7
Ken O’Day, Kellie Meyer, Ross M. Miller, Sonalee Agarwal, Meg Franklin. (2011) Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. Journal of Medical Economics 14:5, 617-627
CrossRef8
Chrissa Sioka, Andreas Fotopoulos, Athanasia Georgiou, Stylianos Papakonstantinou, Sygliti-Henrietta Pelidou, Athanasios P. Kyritsis, John A. Kalef-Ezra. (2011) Body Composition in Ambulatory Patients With Multiple Sclerosis. Journal of Clinical Densitometry 14:4, 465-470
CrossRef9
Francesco Patti, Maria Pia Amato, Maria Trojano, Stefano Bastianello, Maria Rosalia Tola, Orietta Picconi, Sabina Cilia, Salvatore Cottone, Luigi M. E. Grimaldi. (2011) Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). Quality of Life Research
CrossRef10
T. Hayton, J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J. Tozer, D. H. Miller, R. Kapoor. (2011) Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. Journal of Neurology
CrossRef11
Hans Lassmann, Jack van Horssen. (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Letters
CrossRef12
Richard Reynolds, Federico Roncaroli, Richard Nicholas, Bishan Radotra, Djordje Gveric, Owain Howell. (2011) The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathologica 122:2, 155-170
CrossRef13
Regina Schlaeger, Marcus D’Souza, Christian Schindler, Leticia Grize, Ludwig Kappos, Peter Fuhr. (2011) Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clinical Neurophysiology
CrossRef14
Murat Terzi, Esmeray Yilmaz, Bunyamin Sahin, Suleyman Kaplan, Musa Onar. (2011) Examination of the Relationship Between Average Plaque Volume and Clinical and Demographic Characteristics in Multiple Sclerosis Patients Using a Stereological Method. International Journal of Neuroscience 121:7, 366-372
CrossRef15
Andrew R Pachner. (2011) Experimental models of multiple sclerosis. Current Opinion in Neurology 24:3, 291-299
CrossRef16
Jessica DeLong, Hocine Tighiouart, John Stoffel. (2011) Urinary Diversion/Reconstruction for Cases of Catheter Intolerant Secondary Progressive Multiple Sclerosis With Refractory Urinary Symptoms. The Journal of Urology 185:6, 2201-2206
CrossRef17
Hasan A. Al-Hamadani, Atheer S. Abdalla, Atheer J. Al-Saffar. (2011) The course of early-onset multiple sclerosis in Iraqi children. World Journal of Pediatrics
CrossRef18
Jacob J. Sosnoff, Madeline Weikert, Deirdre Dlugonski, Douglas C. Smith, Robert W. Motl. (2011) Quantifying gait impairment in multiple sclerosis using GAITRite™ technology. Gait & Posture 34:1, 145-147
CrossRef19
Ruth Ann Marrie. (2011) Demographic, Genetic, and Environmental Factors That Modify Disease Course. Neurologic Clinics 29:2, 323-341
CrossRef20
Maria Trojano, Damiano Paolicelli, Carla Tortorella, Piero Iaffaldano, Guglielmo Lucchese, Vita Di Renzo, Mariangela D’Onghia. (2011) Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?. Neurologic Clinics 29:2, 309-321
CrossRef21
A. Yahia, S. Ghroubi, C. Mhiri, M.H. Elleuch. (2011) Relationship between muscular strength, gait and postural parameters in multiple sclerosis. Annals of Physical and Rehabilitation Medicine 54:3, 144-155
CrossRef22
Christel Renoux. (2011) Natural History of Multiple Sclerosis: Long-Term Prognostic Factors. Neurologic Clinics 29:2, 293-308
CrossRef23
Cherilyn R. Strader, Cedric J. Pearce, Nicholas H. Oberlies. (2011) Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite. Journal of Natural Products 74:4, 900-907
CrossRef24
Lin-Chung Woung, Hui- Chuan Chung, Jieh-Ren Jou, Kai-Chen Wang, Pai-Huei Peng. (2011) A Comparison of Optic Neuritis in Asian and in Western Countries. Neuro-Ophthalmology 35:2, 65-72
CrossRef25
Brian C. Healy, David Engler, Taha Gholipour, Howard Weiner, Rohit Bakshi, Tanuja Chitnis. (2011) Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. Journal of the Neurological Sciences 303:1-2, 109-113
CrossRef26
Gavin Giovannoni, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven Greenberg. (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. The Lancet Neurology 10:4, 329-337
CrossRef27
Jeffery D. Haines, Matilde Inglese, Patrizia Casaccia. (2011) Axonal Damage in Multiple Sclerosis. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 231-243
CrossRef28
S. Demaille-Wlodyka, C. Donze, P. Givron, P. Gallien. (2011) Self care programs and multiple sclerosis: Physical therapeutics treatment - literature review. Annals of Physical and Rehabilitation Medicine 54:2, 109-128
CrossRef29
Aaron E. Miller. (2011) Multiple Sclerosis: Where Will We Be in 2020?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, 268-279
CrossRef30
S. Nischwitz, B. Müller-Myhsok, F. Weber. (2011) Risk conferring genes in multiple sclerosis. FEBS Letters
CrossRef31
A. Ghezzi, G. Comi, A. Federico. (2011) Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis. Neurological Sciences 32:1, 17-21
CrossRef32
Dong Min Cha, Seong Joon Kim, Jeong Hun Kim, Ho Kyung Choung, Young Suk Yu. (2011) Clinical Features and the Effect of High-Dose Steroid Therapy in Korean Optic Neuritis Patients. Journal of the Korean Ophthalmological Society 52:9, 1083
CrossRef33
Greg L. Plosker. (2011) Interferon-β-1b. CNS Drugs 25:1, 67-88
CrossRef34
Mazen Abu-Mugheisib, Reiner Benecke, Uwe K. Zettl. (2011) Repeated Intrathecal Triamcinolone Acetonide Administration in Progressive Multiple Sclerosis: A Review. Multiple Sclerosis International 2011, 1-8
CrossRef35
Nieves Vélez de Mendizábal, Jorge Carneiro, Ricard V Solé, Joaquín Goñi, Jean Bragard, Ivan Martinez-Forero, Sara Martinez-Pasamar, Jorge Sepulcre, Javier Torrealdea, Francesca Bagnato, Jordi Garcia-Ojalvo, Pablo Villoslada. (2011) Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Systems Biology 5:1, 114
CrossRef36
Giulio Disanto, Antonio J. Berlanga, Adam E. Handel, Andrea E. Para, Amy M. Burrell, Anastasia Fries, Lahiru Handunnetthi, Gabriele C. De Luca, Julia M. Morahan. (2011) Heterogeneity in Multiple Sclerosis: Scratching the Surface of a Complex Disease. Autoimmune Diseases 2011, 1-12
CrossRef37
J. P. Mostert, M. W. Koch, C. Steen, D. J. Heersema, J. C. De Groot, J. De Keyser. (2010) T2 lesions and rate of progression of disability in multiple sclerosis. European Journal of Neurology 17:12, 1471-1475
CrossRef38
Alastair Wilkins, Yoichi Kondo, Jonathan Song, Shujun Liu, Alastair Compston, Joel A. Black, Stephen G. Waxman, Ian D. Duncan. (2010) Slowly Progressive Axonal Degeneration in a Rat Model of Chronic, Nonimmune-Mediated Demyelination. Journal of Neuropathology and Experimental Neurology 69:12, 1256-1269
CrossRef39
Devon S. Conway, Jeffrey A. Cohen. (2010) Multiple sclerosis: Mechanisms of disability accumulation in multiple sclerosis. Nature Reviews Neurology 6:12, 654-655
CrossRef40
Peter O. Behan, Abhijit Chaudhuri. (2010) The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology 18:6, 265-290
CrossRef41
Clare J. Fowler, Catherine Dalton, Jalesh N. Panicker. (2010) Review of Neurologic Diseases for the Urologist. Urologic Clinics of North America 37:4, 517-526
CrossRef42
F. Sellebjerg, D. Barnes, G. Filippini, R. Midgard, X. Montalban, P. Rieckmann, K. Selmaj, L. H. Visser, P. Soelberg Sørensen. 2010. Acute Relapses of Multiple Sclerosis. , 411-419.
CrossRef43
Robert W. Motl. (2010) Physical Activity and Irreversible Disability in Multiple Sclerosis. Exercise and Sport Sciences Reviews 38:4, 186-191
CrossRef44
Theodora A. M. Siepman, Marijke Wefers Bettink-Remeijer, Rogier Q. Hintzen. (2010) Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry. Journal of Neurology 257:10, 1654-1660
CrossRef45
Tülay Terzi, Murat Terzi, Berna Tander, Ferhan Cantürk, Musa Onar. (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. Journal of Clinical Neuroscience 17:10, 1260-1264
CrossRef46
K. Rejdak, S. Jackson, G. Giovannoni. (2010) Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin 95:1, 79-104
CrossRef47
Mario Habek, Fran Borovečki, Vesna V. Brinar. (2010) Genomics in multiple sclerosis. Clinical Neurology and Neurosurgery 112:7, 621-624
CrossRef48
Alon Kalron, Zeevi Dvir, Anat Achiron. (2010) Walking while talking—Difficulties incurred during the initial stages of multiple sclerosis disease process. Gait & Posture 32:3, 332-335
CrossRef49
E. Leray, J. Yaouanq, E. Le Page, M. Coustans, D. Laplaud, J. Oger, G. Edan. (2010) Evidence for a two-stage disability progression in multiple sclerosis. Brain 133:7, 1900-1913
CrossRef50
A. Scalfari, A. Neuhaus, A. Degenhardt, G. P. Rice, P. A. Muraro, M. Daumer, G. C. Ebers. (2010) The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 133:7, 1914-1929
CrossRef51
Amer Awad, Olaf Stüve. (2010) Multiple Sclerosis in the Elderly Patient. Drugs & Aging 27:4, 283-294
CrossRef52
G. Arpaia, P.M. Bavera, D. Caputo, L. Mendozzi, R. Cavarretta, G.B. Agus, M. Milani, E. Ippolito, C. Cimminiello. (2010) Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: A prospective study. Thrombosis Research 125:4, 315-317
CrossRef53
Anneke Van der Walt, Helmut Butzkueven, Scott Kolbe, Mark Marriott, Estella Alexandrou, Melissa Gresle, Gary Egan, Trevor Kilpatrick. (2010) Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade. Pharmacology & Therapeutics 126:1, 82-93
CrossRef54
Christine Betard, Filippo Martinelli Boneschi, Paulo Caramelli. 2010. Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis. .
CrossRef55
Gilles Defer, Bruno Brochet, Jean Pelletier. 2010. Symptômes, formes, évolution. , 11-20.
CrossRef56
Shyi-Jou Chen, Yen-Lin Wang, Jen-Hsin Kao, Shu-Feng Wu, Wen-Tsung Lo, Chia-Cho Wu, Pao-Luh Tao, Chih-Chien Wang, Deh-Ming Chang, Huey-Kang Sytwu. (2009) Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Molecular Immunology 47:2-3, 567-574
CrossRef57
Alexandra Degenhardt, Sreeram V. Ramagopalan, Antonio Scalfari, George C. Ebers. (2009) Clinical prognostic factors in multiple sclerosis: a natural history review. Nature Reviews Neurology 5:12, 672-682
CrossRef58
R.L. Zuvich, J.L. McCauley, M.A. Pericak-Vance, J.L. Haines. (2009) Genetics and pathogenesis of multiple sclerosis. Seminars in Immunology 21:6, 328-333
CrossRef59
Shigeki Tsutsui, Peter K. Stys. (2009) Degeneration versus autoimmunity in multiple sclerosis. Annals of Neurology 66:6, 711-713
CrossRef60
Jerry S. Wolinsky, Tzippy Shochat, Sivan Weiss, David Ladkani. (2009) Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences 286:1-2, 92-98
CrossRef61
M. Debouverie. (2009) Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France. Journal of the Neurological Sciences 286:1-2, 14-17
CrossRef62
Yoh Matsumoto, Il-Kwon Park, Keiko Hiraki, Shin Ohtani, Kuniko Kohyama. (2009) Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats. Immunology 128:1pt2, e250-e261
CrossRef63
Lidia Karabon, Agata Kosmaczewska, Malgorzata Bilinska, Edyta Pawlak, Lidia Ciszak, Anna Jedynak, Anna Jonkisz, Leszek Noga, Anna Pokryszko-Dragan, Magdalena Koszewicz, Irena Frydecka. (2009) The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology 128:1pt2, e787-e796
CrossRef64
Guozhi Tao, Sushmita Datta, Renjie He, Flavia Nelson, Jerry S. Wolinsky, Ponnada A. Narayana. (2009) Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry. Journal of the Neurological Sciences 282:1-2, 39-46
CrossRef65
Luisa M. Villar, Thomas Masterman, Bonaventura Casanova, José Gómez-Rial, Mercedes Espiño, María C. Sádaba, Pedro González-Porqué, Francisco Coret, José C. Álvarez-Cermeño. (2009) CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. Journal of Neuroimmunology 211:1-2, 101-104
CrossRef66
A. Seewann, E-J. Kooi, S. D. Roosendaal, F. Barkhof, P. van der Valk, J. J. G. Geurts. (2009) Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. Acta Neurologica Scandinavica 119:6, 349-355
CrossRef67
Giancarlo Comi. (2009) Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clinical Therapeutics 31:6, 1142-1157
CrossRef68
Florian Deisenhammer. (2009) Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis. CNS Drugs 23:5, 379-396
CrossRef69
E. C. Tallantyre, L. Bo, O. Al-Rawashdeh, T. Owens, C. H. Polman, J. Lowe, N. Evangelou. (2009) Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain 132:5, 1190-1199
CrossRef70
Sasitorn Siritho, Mark S. Freedman. (2009) The prognostic significance of cerebrospinal fluid in multiple sclerosis. Journal of the Neurological Sciences 279:1-2, 21-25
CrossRef71
Ashish Pandit, Jonathan Vadnal, Sara Houston, Ernest Freeman, Jennifer McDonough. (2009) Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. Journal of the Neurological Sciences 279:1-2, 14-20
CrossRef72
Howard L. Weiner. (2009) The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?. Annals of Neurology 65:3, 239-248
CrossRef73
, H. Tremlett, Y. Zhao, V. Devonshire. (2009) Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology 256:3, 374-381
CrossRef74
Marcia Finlayson. (2009) Multiple sclerosis and aging: complexities, concerns and considerations for care. Aging Health 5:1, 89-102
CrossRef75
M. Kerschensteiner, E. Meinl, R. Hohlfeld. (2009) Neuro-immune crosstalk in CNS diseases. Neuroscience 158:3, 1122-1132
CrossRef76
Vanessa Hogan, Kathryn White, Julia Edgar, Alison McGill, Saadia Karim, Mark McLaughlin, Ian Griffiths, Doug Turnbull, Philip Nichols. (2009) Increase in mitochondrial density within axons and supporting cells in response to demyelination in the Plp1 mouse model. Journal of Neuroscience Research 87:2, 452-459
CrossRef77
Thibault Moreau. (2009) Link of the mechanisms of action of glatiramer acetate to its long-term clinical data. Journal of the Neurological Sciences 277, S12-S15
CrossRef78
Loredana La Mantia, George Ebers, Sten Fredrikson, Graziella Filippini, Loredana La Mantia. 2009. Interferon beta for secondary progressive multiple sclerosis. .
CrossRef79
Anners Lerdal, Elisabeth Gulowsen Celius, Torbjørn Moum. (2009) Perceptions of illness and its development in patients with multiple sclerosis: a prospective cohort study. Journal of Advanced Nursing 65:1, 184-192
CrossRef80
Georg Pilz, Peter Wipfler, Gunther Ladurner, Jörg Kraus. (2008) Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today 13:23-24, 1013-1025
CrossRef81
Ute H. Webb. (2008) Early Interferon Beta Treatment in Multiple Sclerosis. Journal of Neuroscience Nursing 40:6, 356-361
CrossRef82
William T. Regenold, Pornima Phatak, Michael J. Makley, Roger D. Stone, Mitchel A. Kling. (2008) Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. Journal of the Neurological Sciences 275:1-2, 106-112
CrossRef83
Christian Confavreux, Sandra Vukusic. (2008) The Clinical Epidemiology of Multiple Sclerosis. Neuroimaging Clinics of North America 18:4, 589-622
CrossRef84
Hans Lassmann. (2008) The Pathologic Substrate of Magnetic Resonance Alterations in Multiple Sclerosis. Neuroimaging Clinics of North America 18:4, 563-576
CrossRef85
R.A. Linker, B.C. Kieseier. (2008) Therapieentscheidungen bei Multipler Sklerose. Der Nervenarzt 79:10, 1123-1134
CrossRef86
M. Debouverie, S. Pittion-Vouyovitch, S. Louis, F. Guillemin, . (2008) Natural history of multiple sclerosis in a population-based cohort. European Journal of Neurology 15:9, 916-921
CrossRef87
Carlo Pozzilli, Luca Prosperini. (2008) Clinical markers of therapeutic response to disease modifying drugs. Neurological Sciences 29:S2, 211-213
CrossRef88
Àlex Rovira, Adelaida León. (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. European Journal of Radiology 67:3, 409-414
CrossRef89
G. C. Ebers, M. Daumer. (2008) Natural history of MS. European Journal of Neurology 15:9, 881-882
CrossRef90
Song-yi Yao, Mohammed Soutto, Subramaniam Sriram. (2008) Preconditioning with cobalt chloride or desferrioxamine protects oligodendrocyte cell line (MO3.13) from tumor necrosis factor-α-mediated cell death. Journal of Neuroscience Research 86:11, 2403-2413
CrossRef91
C. Ytterberg, S. Johansson, M. Andersson, L. Widén Holmqvist, L. Koch. (2008) Variations in functioning and disability in multiple sclerosis. Journal of Neurology 255:7, 967-973
CrossRef92
B. Yamout, W. Barada, R.A. Tohme, A. Mehio-Sibai, R. Khalifeh, T. El-Hajj. (2008) Clinical characteristics of multiple sclerosis in Lebanon. Journal of the Neurological Sciences 270:1-2, 88-93
CrossRef93
Nuhad Abou Zeid, M Tariq Bhatti. (2008) Acute Inflammatory Demyelinating Optic Neuritis. The Neurologist 14:4, 207-223
CrossRef94
Andrei Blokhin, Tamara Vyshkina, Samuel Komoly, Bernadette Kalman. (2008) Variations in Mitochondrial DNA Copy Numbers in MS Brains. Journal of Molecular Neuroscience 35:3, 283-287
CrossRef95
Martha E. Stokely, Puja Garg, Manzoor A. Bhat, Peter Koulen. (2008) Transient 5‐(4‐phenylbutoxy)psoralen (PAP‐1) treatment dissociates developing pathologies in autoimmune optic neuritis into two distinct pathology profiles. Journal of Neuroscience Research 86:9, 2111-2124
CrossRef96
Helen Tremlett, Ingrid Van der Mei, Fotini Pittas, Leigh Blizzard, Glenys Paley, Terence Dwyer, Bruce Taylor, Anne-Louise Ponsonby. (2008) Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 17:6, 565-576
CrossRef97
Kwok-kwong Lau, Winnie Wing-Yin Wong, Bun Sheng, Ignatius Tak-Sun Yu, Bun-Hey Fung, Ho-Lun Li, Ka-Fai Johnny Ma, Lawrence Ka-Sing Wong, Patrick Chung-Ki Li. (2008) The clinical course of multiple sclerosis patients in Hong Kong. Journal of the Neurological Sciences 268:1-2, 78-82
CrossRef98
Ulf Baumhackl. (2008) The search for a balance between short and long-term treatment outcomes in multiple sclerosis. Journal of Neurology 255:S1, 75-83
CrossRef99
H. Butzkueven, S.C. Kolbe, D.J. Jolley, J.Y. Brown, M.J. Cook, I.A.F. van der Mei, P.S. Groom, J. Carey, J. Eckholdt, J.P. Rubio, B.V. Taylor, P.J. Mitchell, G.F. Egan, T.J. Kilpatrick. (2008) Validation of linear cerebral atrophy markers in multiple sclerosis. Journal of Clinical Neuroscience 15:2, 130-137
CrossRef100
C. L. Hirst, A. Pace, T. P. Pickersgill, R. Jones, B. N. McLean, J. P. Zajicek, N. J. Scolding, N. P. Robertson. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology 255:2, 231-238
CrossRef101
G. Comi. (2008) Is it clinically relevant to repair focal multiple sclerosis lesions?. Journal of the Neurological Sciences 265:1-2, 17-20
CrossRef102
Assunta Dal Bianco, Monika Bradl, Josa Frischer, Alexandra Kutzelnigg, Kurt Jellinger, Hans Lassmann. (2008) Multiple sclerosis and Alzheimer's disease. Annals of Neurology 63:2, 174-183
CrossRef103
Alfonso Ciccone, Sandro Beretta, Fabio Brusaferri, Ian Galea, Alessandra Protti, Chiara Spreafico, Alfonso Ciccone. 2008. Corticosteroids for the long-term treatment in multiple sclerosis. .
CrossRef104
S. Chandran, D. Hunt, A. Joannides, C. Zhao, A. Compston, R. J.M Franklin. (2008) Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philosophical Transactions of the Royal Society B: Biological Sciences 363:1489, 171-183
CrossRef105
Gerardo Iuliano, Rosa Napoletano, Antonio Esposito. (2008) Multiple Sclerosis: Relapses and Timing of Remissions. European Neurology 59:1-2, 44-48
CrossRef106
J. P. Mostert, J. C. de Groot, G. S. M. Ramsaransing, M. W. Koch, J. De Keyser. (2007) Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. European Journal of Neurology 14:11, 1210-1215
CrossRef107
D.S. Meier, H.L. Weiner, C.R.G. Guttmann. (2007) MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability. American Journal of Neuroradiology 28:10, 1956-1963
CrossRef108
C. Buttinelli, A. Clemenzi, G. Borriello, F. Denaro, C. Pozzilli, C. Fieschi. (2007) Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. European Journal of Neurology 14:11, 1281-1287
CrossRef109
M. Debouverie, S. Louis, S. Pittion-Vouyovitch, T. Roederer, H. Vespignani. (2007) Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. Journal of Neurology 254:10, 1370-1375
CrossRef110
David H Miller, Siobhan M Leary. (2007) Primary-progressive multiple sclerosis. The Lancet Neurology 6:10, 903-912
CrossRef111
G. C. DeLuca, S. V. Ramagopalan, M. Z. Cader, D. A. Dyment, B. M. Herrera, S. Orton, A. Degenhardt, M. Pugliatti, A. D. Sadovnick, S. Sotgiu, G. C. Ebers. (2007) The role of hereditary spastic paraplegia related genes in multiple sclerosis. Journal of Neurology 254:9, 1221-1226
CrossRef112
Michele Fiorini, Gianluigi Zanusso, Maria Donata Benedetti, Pier Giorgio Righetti, Salvatore Monaco. (2007) Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. PROTEOMICS – CLINICAL APPLICATIONS 1:9, 963-971
CrossRef113
Douglas L. Arnold. (2007) The place of MRI in monitoring the individual MS patient. Journal of the Neurological Sciences 259:1-2, 123-127
CrossRef114
Arnaud Charil, Massimo Filippi. (2007) Inflammatory demyelination and neurodegeneration in early multiple sclerosis. Journal of the Neurological Sciences 259:1-2, 7-15
CrossRef115
J. Palace. (2007) Inflammation versus neurodegeneration: Consequences for treatment. Journal of the Neurological Sciences 259:1-2, 46-49
CrossRef116
Renoux, Christel, Vukusic, Sandra, Mikaeloff, Yann, Edan, Gilles, Clanet, Michel, Dubois, Bénédicte, Debouverie, Marc, Brochet, Bruno, Lebrun-Frenay, Christine, Pelletier, Jean, Moreau, Thibault, Lubetzki, Catherine, Vermersch, Patrick, Roullet, Etienne, Magy, Laurent, Tardieu, Marc, Suissa, Samy, Confavreux, Christian, . (2007) Natural History of Multiple Sclerosis with Childhood Onset. New England Journal of Medicine 356:25, 2603-2613
Full Text117
Sandra Vukusic, Christian Confavreux. (2007) Natural history of multiple sclerosis: risk factors and prognostic indicators. Current Opinion in Neurology 20:3, 269-274
CrossRef118
J. E. Martinez-Rodriguez, D. Cadavid, L. J. Wolansky, L. Pliner, S. D. Cook. (2007) Cladribine in aggressive forms of multiple sclerosis. European Journal of Neurology 14:6, 686-689
CrossRef119
Fred D. Lublin. (2007) The incomplete nature of multiple sclerosis relapse resolution. Journal of the Neurological Sciences 256, S14-S18
CrossRef120
Mohammad Reza Motamed, Neda Najimi, Seyed-Mohammad Fereshtehnejad. (2007) The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery 109:4, 344-349
CrossRef121
Hans Lassmann. (2007) New concepts on progressive multiple sclerosis. Current Neurology and Neuroscience Reports 7:3, 239-244
CrossRef122
Timothy Vollmer. (2007) The natural history of relapses in multiple sclerosis. Journal of the Neurological Sciences 256, S5-S13
CrossRef123
Adrienne Boissy, Robert J. Fox. (2007) Current treatment options in multiple sclerosis. Current Treatment Options in Neurology 9:3, 176-186
CrossRef124
Marcus Koch, Jop Mostert, Dorothea Heersema, Jacques De Keyser. (2007) Progression in multiple sclerosis: Further evidence of an age dependent process. Journal of the Neurological Sciences 255:1-2, 35-41
CrossRef125
Hans Lassmann, Wolfgang Brück, Claudia F. Lucchinetti. (2007) The Immunopathology of Multiple Sclerosis: An Overview. Brain Pathology 17:2, 210-218
CrossRef126
Claire Rice, Neil Scolding. (2007) Strategies for achieving and monitoring myelin repair. Journal of Neurology 254:3, 275-283
CrossRef127
Philip L. De Jager, David A. Hafler. (2007) New Therapeutic Approaches for Multiple Sclerosis. Annual Review of Medicine 58:1, 417-432
CrossRef128
Paul O’Connor. (2007) Natalizumab and the role of α 4 -integrin antagonism in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy 7:1, 123-136
CrossRef129
Istvan Pirko, John H. Noseworthy. 2007. Demyelinating Disorders of the Central Nervous System. , 1103-1133.
CrossRef130
Jerry S. Wolinsky, Ponnada A. Narayana, Paul O'Connor, Patricia K. Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani, . (2007) Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology 61:1, 14-24
CrossRef131
V. Petiot, C. Quantin, G. Le Teuff, M. Chavance, C. Binquet, M. Abrahamowicz, T. Moreau. (2007) Disability Evolution in Multiple Sclerosis: How to Deal with Missing Transition Times in the Markov Model?. Neuroepidemiology 28:1, 56-64
CrossRef132
Mike Boggild. (2006) Rationale and experience with combination therapies in multiple sclerosis. Journal of Neurology 253:S6, vi45-vi51
CrossRef133
Corey C. Ford. (2006) Long-term experience with current disease-modifying drugs in multiple sclerosis. Journal of Neurology 253:S6, vi37-vi44
CrossRef134
Bernd C. Kieseier. (2006) Assessing long-term effects of disease-modifying drugs. Journal of Neurology 253:S6, vi23-vi30
CrossRef135
Xavier Montalban. (2006) The importance of long-term data in multiple sclerosis. Journal of Neurology 253:S6, vi9-vi15
CrossRef136
2006. Multiple Sclerosis. .
CrossRef137
Allan MacKenzie-Graham, Matthew R. Tinsley, Kaanan P. Shah, Cynthia Aguilar, Lauren V. Strickland, Jyl Boline, Melanie Martin, Laurie Morales, David W. Shattuck, Russell E. Jacobs, Rhonda R. Voskuhl, Arthur W. Toga. (2006) Cerebellar cortical atrophy in experimental autoimmune encephalomyelitis. NeuroImage 32:3, 1016-1023
CrossRef138
Naoyuki Tanuma, Hiroshi Sakuma, Atsushi Sasaki, Yoh Matsumoto. (2006) Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathologica 112:2, 195-204
CrossRef139
Suhayl Dhib-Jalbut, Douglas L. Arnold, Don W. Cleveland, Mark Fisher, Robert M. Friedlander, M. Maral Mouradian, Serge Przedborski, Bruce D. Trapp, Tony Wyss-Coray, V. Wee Yong. (2006) Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Journal of Neuroimmunology 176:1-2, 198-215
CrossRef140
T. Ziemssen, H. Wilhelm, F. Ziemssen. (2006) Multiple Sklerose. Der Ophthalmologe 103:7, 621-643
CrossRef141
Nuray Yozbatıran, Ferdi Baskurt, Zeliha Baskurt, Serkan Ozakbas, Egemen Idiman. (2006) Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients. Journal of the Neurological Sciences 246:1-2, 117-122
CrossRef142
Helen Andrews, Kathryn White, Christine Thomson, Julia Edgar, David Bates, Ian Griffiths, Douglass Turnbull, Philip Nichols. (2006) Increased axonal mitochondrial activity as an adaptation to myelin deficiency in theShiverer mouse. Journal of Neuroscience Research 83:8, 1533-1539
CrossRef143
H. L. Zwibel. (2006) Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients*. Acta Neurologica Scandinavica 113:6, 378-386
CrossRef144
A. Compston. (2006) The basis for treatment in multiple sclerosis. Acta Neurologica Scandinavica 113:s183, 41-47
CrossRef145
Francesco Lolli, Paolo Rovero, Mario Chelli, Anna Maria Papini. (2006) Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics 6:5, 781-794
CrossRef146
F. Patti, A. Pappalardo, C. Florio, G. Politi, T. Fiorilla, E. Reggio, A. Reggio. (2006) Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurologica Scandinavica 113:4, 241-247
CrossRef147
Roberto Bergamaschi. (2006) Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Review of Neurotherapeutics 6:3, 357-364
CrossRef148
Jordi Río, Carlos Nos, Mar Tintoré, Nieves Téllez, Ingrid Galán, Raúl Pelayo, Manuel Comabella, Xavier Montalban. (2006) Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients. Annals of Neurology 59:2, 344-352
CrossRef149
A. J. Coles, A. Cox, E. Page, J. Jones, S. A. Trip, J. Deans, S. Seaman, D. H. Miller, G. Hale, H. Waldmann, D. A. Compston. (2006) The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology 253:1, 98-108
CrossRef150
David C. Mohr, Daniel Pelletier. (2006) A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain, Behavior, and Immunity 20:1, 27-36
CrossRef151
C. Binquet, C. Quantin, G. Le Teuff, J.F. Pagliano, M. Abrahamowicz, T. Moreau. (2006) The Prognostic Value of Initial Relapses on the Evolution of Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neuroepidemiology 27:1, 45-54
CrossRef152
Hans Lassmann. (2005) Mechanisms of multiple sclerosis. Drug Discovery Today: Disease Mechanisms 2:4, 447-452
CrossRef153
F. Sellebjerg, D. Barnes, G. Filippini, R. Midgard, X. Montalban, P. Rieckmann, K. Selmaj, L. H. Visser, P. S. Sorensen. (2005) EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. European Journal of Neurology 12:12, 939-946
CrossRef154
Linda M. Griffith, Steven Z. Pavletic, Alan Tyndall, Christopher N. Bredeson, James D. Bowen, Richard W. Childs, Alois Gratwohl, Jacob M. van Laar, Maureen D. Mayes, Roland Martin, Peter A. McSweeney, Paolo A. Muraro, Harry Openshaw, Riccardo Saccardi, Brenda M. Sandmaier, Stephen J. Forman, Richard A. Nash. (2005) Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Transplantation 11:11, 862-870
CrossRef155
Alex J Mitchell, Julián Benito-León, José-Manuel Morales González, Jesús Rivera-Navarro. (2005) Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. The Lancet Neurology 4:9, 556-566
CrossRef156
Ph. Devos. (2005) Étiopathogénie de la maladie d’alzheimer, de la maladie de parkinson et de la sclerose en plaques : le lait n’est pas en cause. Cahiers de Nutrition et de Diététique 40, 54-56
CrossRef157
Domenico M Mezzapesa, Marco Rovaris, Massimo Filippi. (2005) Glatiramer acetate in multiple sclerosis. Expert Review of Neurotherapeutics 5:4, 451-458
CrossRef158
Giancarlo Comi, Massimo Filippi. (2005) Clinical trials in multiple sclerosis: methodological issues. Current Opinion in Neurology 18:3, 245-252
CrossRef159
Xavier Montalban. (2005) Primary progressive multiple sclerosis. Current Opinion in Neurology 18:3, 261-266
CrossRef160
Alexandra Kutzelnigg, Hans Lassmann. (2005) Cortical lesions and brain atrophy in MS. Journal of the Neurological Sciences 233:1-2, 55-59
CrossRef161
Gareth Pryce, David Baker. (2005) Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends in Neurosciences 28:5, 272-276
CrossRef162
David Miller, Frederik Barkhof, Xavier Montalban, Alan Thompson, Massimo Filippi. (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. The Lancet Neurology 4:5, 281-288
CrossRef163
Manabu Osoegawa, Ryuji Miyagishi, Hirofumi Ochi, Itta Nakamura, Masaaki Niino, Seiji Kikuchi, Hiroyuki Murai, Toshiyuki Fukazawa, Motozumi Minohara, Kunio Tashiro, Jun-ichi Kira. (2005) Platelet-activating factor receptor gene polymorphism in Japanese patients with multiple sclerosis. Journal of Neuroimmunology 161:1-2, 195-198
CrossRef164
Orhun H. Kantarci, Brian G. Weinshenker. (2005) Natural history of multiple sclerosis. Neurologic Clinics 23:1, 17-38
CrossRef165
Fred D. Lublin. (2005) Clinical features and diagnosis of multiple sclerosis. Neurologic Clinics 23:1, 1-15
CrossRef166
Claudia F. Lucchinetti, Joseph Parisi, Wolfgang Bruck. (2005) The pathology of multiple sclerosis. Neurologic Clinics 23:1, 77-105
CrossRef167
John W. Peterson, Bruce D. Trapp. (2005) Neuropathobiology of multiple sclerosis. Neurologic Clinics 23:1, 107-129
CrossRef168
G PA Rice, GC Ebers, S Fredrikson, D Mason, F Tesser, G Filippini, George PA Rice. 2005. Interferon beta for secondary progressive multiple sclerosis. .
CrossRef169
Siobhan M Leary, Alan J Thompson. (2005) Primary Progressive Multiple Sclerosis. CNS Drugs 19:5, 369-376
CrossRef170
K. P. Johnson, C. C. Ford, R. P. Lisak, J. S. Wolinsky. (2005) Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurologica Scandinavica 111:1, 42-47
CrossRef171
Manabu OSOEGAWA, Masaaki NIINO, Masahito TANAKA, Seiji KIKUCHI, Hiroyuki MURAI, Toshiyuki FUKAZAWA, Motozumi MINOHARA, Ryuji MIYAGISHI, Takayuki TANIWAKI, Kunio TASHIRO, Jun-ichi KIRA. (2005) Comparison of the Clinical Courses of the Opticospinal and Conventional Forms of Multiple Sclerosis in Japan. Internal Medicine 44:9, 934-938
CrossRef172
Maria Pia Amato, Jerome Grimaud, Iuliana Achiti, Maria Letizia Bartolozzi, Patrice Adeleine, Hans-Peter Hartung, Ludwig Kappos, Alan Thompson, Maria Trojano, Sandra Vukusic, Christian Confavreux. (2004) European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology 251:12, 1472-1480
CrossRef173
A. Achiron, G. Lavie, I. Kishner, Y. Stern, I. Sarova-Pinhas, T. Ben-Aharon, Y. Barak, H. Raz, M. Lavie, T. Barliya, M. Faibel, I.R. Cohen, M. Mandel. (2004) T cell vaccination in multiple sclerosis relapsing–remitting nonresponders patients. Clinical Immunology 113:2, 155-160
CrossRef174
Claire Rice, Christopher Halfpenny, Neil Scolding. (2004) Cell therapy in demyelinating diseases. NeuroRX 1:4, 415-423
CrossRef175
Anat Achiron. (2004) Predicting the course of relapsing-remitting MS using longitudinal disability curves. Journal of Neurology 251:S5, v65-v68
CrossRef176
Anthony Traboulsee. (2004) MRI: role in optimising treatment. Journal of Neurology 251:S5, v36-v41
CrossRef177
Athanasios Fassas, Vasilios K Kimiskidis. (2004) Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. Journal of the Neurological Sciences 223:1, 53-58
CrossRef178
Raija L.P Lindberg, Corline J.A De Groot, Ulrich Certa, Rivka Ravid, Francine Hoffmann, Ludwig Kappos, David Leppert. (2004) Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. Journal of Neuroimmunology 152:1-2, 154-167
CrossRef179
Athanasios Fassas, Richard Nash. (2004) Multiple sclerosis. Best Practice & Research Clinical Haematology 17:2, 247-262
CrossRef180
Jaume Sastre-Garriga, Gordon T Ingle, Declan T Chard, Lluı́s Ramió-Torrentà, David H Miller, Alan J Thompson. (2004) Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. NeuroImage 22:1, 353-359
CrossRef181
Manabu Osoegawa, Masaaki Niino, Hirofumi Ochi, Seiji Kikuchi, Hiroyuki Murai, Toshiyuki Fukazawa, Motozumi Minohara, Kunio Tashiro, Jun-ichi Kira. (2004) Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis. Journal of Neuroimmunology 150:1-2, 150-156
CrossRef182
Richard E Gonsette. (2004) A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Expert Opinion on Pharmacotherapy 5:4, 747-765
CrossRef183
David H. Miller. (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRX 1:2, 284-294
CrossRef184
David A. Hafler. (2004) Multiple sclerosis. Journal of Clinical Investigation 113:6, 788-794
CrossRef185
Richard K. Burt, Larissa Verda, Laisvyde Statkute, Yu Oyama. (2004) Unique clinical aspects of hematopoietic stem cell transplantation for autoimmune diseases. Current Opinion in Organ Transplantation 9:1, 49-53
CrossRef186
Jacques De Keyser, Esther Zeinstra, Nadine Wilczak. (2004) Astrocytic β2-adrenergic receptors and multiple sclerosis. Neurobiology of Disease 15:2, 331-339
CrossRef187
Jacques De Keyser, Esther Zeinstra, Jop Mostert, Nadine Wilczak. (2004) β2-Adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends in Pharmacological Sciences 25:2, 67-71
CrossRef188
Claire Rice, Christopher Halfpenny, Neil Scolding. (2004) Cell therapy in demyelinating diseases. NeuroRX 1:4, 415
CrossRef189
Gavin Giovannoni. (2004) Management of Secondary-Progressive Multiple Sclerosis. CNS Drugs 18:10, 653-669
CrossRef190
David H. Miller. (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRX 1:2, 284
CrossRef191
X. Lin, L. D. Blumhardt, C. S. Constantinescu. (2003) The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurologica Scandinavica 108:6, 401-406
CrossRef192
Athanasios Fassas, Aristide Kazis. (2003) High-Dose Immunosuppression and Autologous Hematopoietic Stem Cell Rescue for Severe Multiple Sclerosis. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 12:6, 701-711
CrossRef193
Michael D. Kaufman, Susan K. Johnson, David Moyer, Jessica Bivens, H. James Norton. (2003) Multiple Sclerosis. American Journal of Physical Medicine & Rehabilitation 82:8, 582-590
CrossRef194
Paolo A. Muraro, Riccardo Cassiani Ingoni, Roland Martin. (2003) Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challenges. Current Opinion in Neurology 16:3, 299-305
CrossRef195
J. C. Debruyne, J. Versijpt, K. J. Van Laere, F. De Vos, J. Keppens, K. Strijckmans, E. Achten, G. Slegers, R. A. Dierckx, J. Korf, J. L. De Reuck. (2003) PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. European Journal of Neurology 10:3, 257-264
CrossRef196
(2003) Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 348:16, 1598-1599
Full Text197
Abhijit Chaudhuri, Peter O Behan. (2003) Mitoxantrone trial in multiple sclerosis. The Lancet 361:9363, 1133-1134
CrossRef198
Daniel R. Touchette, Tracy L. Durgin, Lee A. Wanke, Donald E. Goodkin. (2003) A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clinical Therapeutics 25:2, 611-634
CrossRef199
Sandra Vukusic, Christian Confavreux. (2003) Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. Journal of the Neurological Sciences 206:2, 135-137
CrossRef200
Jun-ichi Kira. (2003) Multiple sclerosis in the Japanese population. The Lancet Neurology 2:2, 117-127
CrossRef201
C Bjartmar, J.R Wujek, B.D Trapp. (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. Journal of the Neurological Sciences 206:2, 165-171
CrossRef202
Jackie Palace. (2003) Clinical and laboratory characteristics of secondary progressive MS. Journal of the Neurological Sciences 206:2, 131-134
CrossRef203
Sandra Vukusic, Christian Confavreux. (2003) Primary and secondary progressive multiple sclerosis. Journal of the Neurological Sciences 206:2, 153-155
CrossRef204
Carl Bjartmar, Bruce D. Trapp. (2003) Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotoxicity Research 5:1-2, 157-164
CrossRef205
Loren A. Rolak. 2003. Pathophysiology and Clinical Features of Multiple Sclerosis. , 408-410.
CrossRef206
N. Chandler, S. Jacobson, P. Esposito, R. Connolly, T.C. Theoharides. (2002) Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice. Brain, Behavior, and Immunity 16:6, 757-763
CrossRef207
M. P. Pender, N. P. Wolfe. (2002) Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. Internal Medicine Journal 32:11, 554-563
CrossRef208
Robert Zivadinov, Marino Zorzon. (2002) Is Gadolinium Enhancement Predictive of the Development of Brain Atrophy in Multiple Sclerosis? A Review of the Literature. Journal of Neuroimaging 12:4, 302-309
CrossRef209
Christian Confavreux, Sandra Vukusic. (2002) Natural history of multiple sclerosis: implications for counselling and therapy. Current Opinion in Neurology 15:3, 257-266
CrossRef210
David H Mattson. (2002) Update on the diagnosis of multiple sclerosis. Expert Review of Neurotherapeutics 2:3, 319-328
CrossRef211
Christopher Halfpenny, Tracey Benn, Neil Scolding. (2002) Cell transplantation, myelin repair, and multiple sclerosis. The Lancet Neurology 1:1, 31-40
CrossRef212
Maria Trojano, Maria Liguori, Giovanni Bosco Zimatore, Roberto Bugarini, Carlo Avolio, Damiano Paolicelli, Fabrizio Giuliani, Francesca De Robertis, Maria Giovanna Marrosu, Paolo Livrea. (2002) Age-related disability in multiple sclerosis. Annals of Neurology 51:4, 475-480
CrossRef213
Alastair Compston, Alasdair Coles. (2002) Multiple sclerosis. The Lancet 359:9313, 1221-1231
CrossRef214
B. Mark Keegan, John H. Noseworthy. (2002) M
ULTIPLE SCLEROSIS . Annual Review of Medicine 53:1, 285-302
CrossRef215
Brex, Peter A., Ciccarelli, Olga, O'Riordan, Jonathon I., Sailer, Michael, Thompson, Alan J., Miller, David H., . (2002) A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis. New England Journal of Medicine 346:3, 158-164
Full Text216
Richard K. Burt, Shimon Slavin, William H. Burns, Alberto M. Marmont. (2002) Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: Getting closer to a cure?. International Journal of Hematology 76:S1, 226-247
CrossRef217
George PA Rice, Barbara Incorvaia, Luca M. Munari, George Ebers, Chris Polman, Roberto D'Amico, Elena Parmelli, Graziella Filippini, Graziella Filippini. 2001. Interferon in relapsing-remitting multiple sclerosis. .
CrossRef218
O. A. Khan, A. C. Tselis, J. A. Kamholz, J. Y. Garbern, R. A. Lewis, R. P. Lisak. (2001) Response To Greenstein's letter. European Journal of Neurology 8:5, 505-506
CrossRef219
Jeffrey I. Greenstein. (2001) Appropriate design and outcome measures in multiple sclerosis clinical trials. European Journal of Neurology 8:5, 503-504
CrossRef220
Brian G Weinshenker. (2001) Bayesian analysis: what does it add to studies of the natural history of MS?. Journal of the Neurological Sciences 189:1-2, 1-2
CrossRef221
X. Lin, L.D. Blumhardt. (2001) Inflammation and atrophy in multiple sclerosis: MRI associations with disease course. Journal of the Neurological Sciences 189:1-2, 99-104
CrossRef222
Carl Bjartmar, Bruce D. Trapp. (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Current Opinion in Neurology 14:3, 271-278
CrossRef223
Paul M. Matthews, Douglas L. Arnold. (2001) Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Current Opinion in Neurology 14:3, 279-287
CrossRef224
Heather J. MacLean, Mark S. Freedman. (2001) Immunologic therapy for relapsing-remitting multiple sclerosis. Current Neurology and Neuroscience Reports 1:3, 277-285
CrossRef225
Peter J. Snyder, Joseph C. Cappelleri, Catherine J. Archibald, John D. Fisk. (2001) Improved detection of differential information-processing speed deficits between two disease-course types of multiple sclerosis.. Neuropsychology 15:4, 617-625
CrossRef226
McDonald, W. Ian. (2000) Relapse, Remission, and Progression in Multiple Sclerosis. New England Journal of Medicine 343:20, 1486-1487
Full Text
